Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (Q24200697)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients	scientific article

Statements

scholarly article

0 references

0 references

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients (English)

0 references

Cytomegalovirus

0 references

5

object named as

Jonathan C Craig

author given names

Jonathan C

author last names

Craig

1 reference

PubMed publication ID

21 October 2023

Giovanni Strippoli

4

object named as

Giovanni FM Strippoli

author given names

Giovanni F M

author last names

Strippoli

1 reference

PubMed publication ID

21 October 2023

3

object named as

Angela C Webster

author given names

Angela C

author last names

Webster

1 reference

PubMed publication ID

21 October 2023

Maleeka Ladhani

2

object named as

Maleeka Ladhani

author given names

Maleeka

author last names

Ladhani

1 reference

PubMed publication ID

21 October 2023

author name string

Elisabeth M Hodson

1

author given names

Elisabeth M

author last names

Hodson

1 reference

PubMed publication ID

21 October 2023

publication date

28 February 2013

0 references

Cochrane Database of Systematic Reviews

0 references

Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Comparison of Intravenous Ganciclovir Followed by Oral Acyclovir with Intravenous Ganciclovir Alone for Prevention of Cytomegalovirus and Epstein‐Barr Virus Disease After Liver Transplantation in Children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Recombinant Phenotyping of Cytomegalovirus Sequence Variants Detected After 200 or 100 Days of Valganciclovir Prophylaxis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Response to questions regarding the design and results of the IMPACT trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

IMPACT Trial Results Should Not Change Current Standard of Care of 100 Days for Cytomegalovirus Prophylaxis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Ganciclovir Pharmacokinetic Parameters Do Not Change When Extending Valganciclovir Cytomegalovirus Prophylaxis From 100 to 200 Days

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytom

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Studies evaluating high-dose acyclovir, intravenous immune globulin, and cytomegalovirus hyperimmunoglobulin for prophylaxis against cytomegalovirus in kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Prophylaxis against CMV infection in transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: a prospective, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Prophylaxis of cytomegalovirus infection in renal transplantation: new data for an old problem

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Ganciclovir prophylaxis decreases frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Prospective randomized trial to assess the value of preemptive oral therapy for CMV infection following liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

A Randomized Prospective Trial of Acyclovir and Immune Globulin Prophylaxis in Liver Transplant Recipients Receiving OKT3 Therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients. Longitudinal follow-up of CMV pp65 antigenemia assay

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

24 Weeks of Valganciclovir Prophylaxis in Children After Renal Transplantation: A 4-Year Experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

WITHDRAWN: Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Identifying relevant studies for systematic reviews

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Infection in organ-transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Meta-analysis of prophylaxis of CMV disease in solid organ transplantation: is Ganciclovir a superior agent to Acyclovir?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

International consensus guidelines on the management of cytomegalovirus in solid organ transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Antiviral medication for preventing cytomegalovirus disease in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

21 January 2018

A Trial of Vidarabine for Cytomegalovirus Infection in Renal Transplant Patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Solid organ transplantation: results and implications of acyclovir use in liver transplants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Acyclovir in immunocompromised patients with cytomegalovirus disease. A controlled trial at one institution

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Hyperimmuneglobulin for cytomegalovirus prophylaxis following heart transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Polymerase chain reaction-triggered preemptive or deferred therapy to control cytomegalovirus-associated morbidity and costs in renal transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral ganciclovir in the prevention of cytomegalovirus infection in postkidney transplant "CMV at risk" recipients: a controlled, comparative study of two regimens (750 mg Bid and 500 mg Bid)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effective oral ganciclovir prophylaxis against cytomegalovirus disease in heart transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparative study of 500 mg BID and 250 mg BID of prophylactic oral ganciclovir in post-kidney transplant "CMV at risk" recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus immune globulin after liver transplantation: a cost-effectiveness analysis 1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus prophylaxis with antiviral agents in solid organ transplantation: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

The economic impact of cytomegalovirus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

CYTOMEGALOVIRUS ANTIGENEMIA DIRECTED PRE-EMPTIVE PROPHYLAXIS WITH ORAL VERSUS I.V. GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytomegalovirus in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Valganciclovir prophylaxis against cytomegalovirus impairs lymphocyte proliferation and activation in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003774.PUB4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/14651858.CD003774.PUB4

0 references

release_i3q4mqjyf5duboughww42ykreu

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24200697&oldid=1994365736"